Alerts

New conditions for Di-Gesic and Doloxene (dextropropoxyphene) took effect on 10 October 2013 to ensure safe use, changing how these pain-killers are prescribed and supplied.

Recall due to potential for incorrect blood glucose results.

Recall due to potential for protruding needles.

The TGA has tested two samples of a product labelled Prosolution tablets and found that one counterfeit sample contained tadalafil and sildenafil.

Recall due to replacement due to potential for breakdown.

Recall due to replacement due to potential for miscalibration.

Monitoring communication

New conditions on Di-Gesic and Doloxene (dextropropoxyphene) will change how these pain-killers are prescribed and supplied to ensure safe use from 10 October 2023.

Unlocated devices following recall for product correction.

Changes to radio frequency (RF) spectrums in Australia could affect a small number of biomedical telemetry devices used in hospitals.

Recall for product correction due to potential for aluminium tubing to break.

Recall for product correction due to potential for injury.

Recall for product correction due to potential for handle to break.

Recall due to replacement with newer model.

A hazard alert has been issued to cardiologists and surgeons regarding some models of Cognis Cardiac Resynchronisation Therapy Defibrillators (CRT-Ds) and Teligen Implantable Cardioverter Defibrillators (ICDs).

Hazard alert due to updated surgical instructions and additional quality check.